Abstract
Background: Migraine is a chronic neurological disorder with a high prevalence of psychiatric comorbidity, including anxiety and depression, which compound functional impairment and reduce health-related quality of life (HRQoL). Repetitive transcranial magnetic stimulation (rTMS) is a non-pharmacological neuromodulatory intervention targeting both pain and affective circuits; however, predictors of HRQoL improvement following rTMS remain poorly characterized. Methods: In this exploratory observational study, 32 adults with migraines underwent 10–40 rTMS sessions. Quality of life was assessed using the WHOQOL-BREF and Migraine-Specific Quality of Life Questionnaire (Migraine-QoL). Psychiatric burden, headache impact, and disability were evaluated using HAMA, HAMD, HIT-6, and MIDAS at baseline and post-intervention. Paired t-tests, Spearman correlations, and linear regression identified predictors of QoL change. Results: Both WHOQOL-BREF and Migraine-QoL improved significantly following rTMS (p < 0.001). Antipsychotic use was associated with greater overall QoL improvement (p = 0.026). Given the very small subgroup size (n = 7), this finding should be interpreted with extreme caution and considered hypothesis-generating only. Higher baseline HIT-6 and HAMA correlated with greater Migraine-QoL gains (p = 0.001 and p = 0.013). In multivariate regression, higher headache severity independently predicted Migraine-QoL improvement (R2 = 0.514, p < 0.001). Conclusions: rTMS produced clinically meaningful QoL improvements in migraine. Headache burden emerged as an independent predictor, while associations with anxiety severity and antipsychotic use should be considered exploratory.
1. Introduction
1.1. Epidemiology and Risk Factors
Migraine is a chronic neurological disorder characterized by recurrent attacks of moderate to severe headache, typically pulsating, often unilateral, and commonly associated with nausea, vomiting, photophobia, and phonophobia, with attacks lasting 4–72 h and causing significant functional impairment [1]. Migraine most often begins at puberty and generally affects those aged between 35 and 45 years. It is more common in women, possibly because of hormonal influences [2].
Several mechanisms have been proposed to explain migraine, and a wide range of risk factors have been identified. These include advanced age, head trauma, lower socioeconomic status, stress, sleep disturbances, obesity, chronic pain syndromes, caffeine or medication overuse, and pro-inflammatory or pro-thrombotic states. Chronic migraine, a distinct subtype, is additionally associated with ineffective acute migraine treatment and sustained medication overuse. Demographic characteristics such as sex and race, along with lifestyle factors including excessive caffeine consumption, weight gain, and sleep disorders, further contribute to migraine risk. Moreover, migraine may be linked to several related syndromes—such as somnambulism, cyclic vomiting, abdominal migraine, benign paroxysmal vertigo, benign paroxysmal torticollis, and confusional migraine—each characterized by distinct clinical features, durations, and prevalence patterns [3].
1.2. Clinical Burden, Psychiatric Comorbidity, and Quality of Life
Migraine exerts a strong influence on disability, functional capacity, and psychological well-being. Migraine-related disability is often under-recognized and inadequately addressed in clinical practice, contributing to reduced quality of life and increased functional impairment [4]. Recurrent attacks cause functional impairments encompassing both physical and psychological effects, occurring during and in the aftermath of attacks [5,6,7,8]. Comparing migraine sufferers and non-migraine sufferers, migraine sufferers have worse subjective well-being and lower quality of life [4]. The clinical burden of migraine is increasingly recognized as a continuous state rather than a series of isolated events. Patients frequently experience an “interictal burden,” characterized by anticipatory anxiety, cognitive “fog” and perceived stigma, which persists even between attacks [9]. The burden of migraine and the challenge in managing it are increased by the comorbid psychiatric conditions that occur in association with it.
Migraine is strongly associated with many psychiatric disorders, involving depression, anxiety, and bipolar disorders [10]. This cumulative toll results in a profound erosion of Health-Related Quality of Life (HRQoL), affecting professional productivity, social participation, and psychological well-being [11]. For decades, migraine management relied on repurposed medications such as beta-blockers, tricyclic antidepressants, and anticonvulsants. While effective for some, these treatments are often limited by poor adherence due to systemic side effects like fatigue, weight gain, and cognitive impairment [12]. The therapeutic landscape underwent a paradigm shift with the elevation of Calcitonin Gene-Related Peptide (CGRP)-targeted therapies—including monoclonal antibodies (e.g., erenumab, fremanezumab) and small-molecule “gepants” (e.g., atogepant, rimegepant)—to first-line status. Unlike older drugs, these agents were designed specifically for migraine pathophysiology and offer a rapid onset [12], dual action (acute relief and prevention) and improved safety (minimal vasoconstrictive risk, making them safer for patients with cardiovascular contraindications compared to traditional triptans) [13]. Despite these advances, approximately 30–40% of patients remain refractory to CGRP-targeted therapies or prefer non-pharmacological interventions to avoid systemic medication [12]. This has led to the integration of non-invasive neuromodulation, most notably Repetitive Transcranial Magnetic Stimulation (rTMS). By delivering magnetic pulses to modulate cortical excitability—targeting areas such as the primary motor cortex (M1) for pain processing or the dorsolateral prefrontal cortex (DLPFC) for mood and frequency regulation—rTMS offers a localized treatment with a unique safety profile. Recent clinical evidence suggests that high-frequency rTMS protocols (10–20 Hz) not only reduce headache frequency but also provide superior improvements in patient-reported QoL metrics, by addressing the emotional and functional dimensions of the disease [2,14].
The psychiatric dimension of migraine is central to understanding its impact on quality of life. Migraine is not solely a pain disorder; it constitutes a significant neuropsychiatric condition with profound implications for mental health, psychological functioning, and social participation. Epidemiological data consistently demonstrate that individuals with migraine have two- to five-fold higher rates of major depressive disorder and generalized anxiety disorder compared to headache-free controls [15,16]. The relationship between migraine and psychiatric comorbidity is bidirectional: affective disorders can lower the pain threshold and increase central sensitization, while chronic pain and disability in turn exacerbate depressive and anxious symptomatology. This bidirectionality creates a vicious cycle that is particularly damaging to long-term quality of life. Furthermore, post-traumatic stress disorder, panic disorder, and obsessive–compulsive disorder have also been reported at elevated rates in migraine populations, further underscoring the importance of integrated psychiatric assessment in this patient group [17]. Psychiatric comorbidities in migraine are not incidental—they are mechanistically linked through shared dysregulation of serotonergic, dopaminergic, and noradrenergic neurotransmitter systems, as well as hypothalamic–pituitary–adrenal (HPA) axis dysfunction, which drives both mood dysregulation and central pain sensitization.
1.3. Treatment Landscape and the Role of rTMS
RTMS represents a particularly promising intervention from a psychiatric standpoint. Unlike purely analgesic or anti-inflammatory pharmacological approaches, rTMS directly targets cortical and subcortical circuits implicated in both pain processing and affective regulation. High-frequency stimulation of the left dorsolateral prefrontal cortex (DLPFC), a region consistently hypoactive in depression, has demonstrated antidepressant efficacy in multiple randomized controlled trials and has received regulatory approval for major depressive disorder in several countries [18,19]. In migraine, the same prefrontal targets may modulate descending pain inhibitory pathways via connections to the periaqueductal gray (PAG) and anterior cingulate cortex (ACC), while simultaneously addressing the affective components of suffering that conventional migraine treatments neglect [20,21]. Intermittent theta burst stimulation (iTBS), the protocol employed in the present study, has been shown to produce rapid and sustained neuroplastic changes in cortical excitability, making it a particularly efficient rTMS variant for outpatient clinical settings [22,23]. The dual action of rTMS—modulating pain and mood—makes it an especially relevant intervention for a population in which psychiatric comorbidity is the rule rather than the exception, and in which quality of life is determined not only by headache frequency but also by emotional functioning, cognitive performance, and daily disability.
1.4. Rationale and Study Aims
Despite growing interest in non-pharmacological neuromodulation, a critical gap remains in the literature: few studies have examined which clinical or psychiatric baseline characteristics predict quality-of-life improvement following rTMS in migraine patients. Most existing trials have focused on headache frequency and pain intensity as primary outcomes, using QoL measures only as secondary endpoints if at all. This is a significant limitation because, from the patient’s perspective, regaining functional capacity, emotional well-being, and social participation—rather than mere pain reduction—often represents the most meaningful treatment goal. Identifying predictors of QoL improvement is clinically valuable because it can support patient stratification, enabling clinicians to direct this resource-intensive intervention toward those most likely to benefit. Baseline psychiatric burden, measured through validated instruments such as the Hamilton Anxiety Scale (HAMA) and Hamilton Depression Rating Scale (HAMD), may be particularly informative in this regard. The selection of baseline measures was guided by the hypothesis that psychiatric symptom burden, headache impact, and functional disability each independently contribute to migraine-related QoL impairment, and that their baseline levels may differentially predict the magnitude of QoL improvement following a neuromodulatory intervention targeting both pain and affective circuits. This exploratory study aims to identify baseline clinical and psychiatric predictors of quality-of-life improvement in adults with migraine undergoing rTMS.
2. Materials and Methods
Between October 2023 and December 2025, we enrolled participants diagnosed with migraine according to ICHD Guidelines [24] who presented at a local neurology clinic for rTMS sessions and prospectively collected sociodemographic and clinical data. Inclusion criteria were: (1) confirmed diagnosis of migraine according to ICHD-3 criteria; (2) age 18 years or older; and (3) ability to provide written informed consent. Exclusion criteria were: (1) contraindications to rTMS (history of epilepsy, intracranial metallic implants, pacemaker); (2) active psychotic disorder or current manic episode; (3) pregnancy; and (4) severe cognitive impairment precluding scale administration. The study obtained approval from the local ethics committee of Inter Health Systems SRL—Emerald Medical Center, number 1/01.09.2023 on 20 October 2023. All participants provided their informed consent before inclusion. The study was conducted in accordance with the Declaration of Helsinki [25].
Participants underwent 10 to 40 sessions of rTMS performed by a trained clinician. The protocol used was intermittent Theta Burst Stimulation with 5–10 Hz, 20 pulses per train, 20 trains, 2 s of stimulation, 8 s pause between each train. The specific magnetic stimulation machine was a MagVenture MagPro R20, figure-of-eight coil for the stimulation and either round or parabolic coil was used to determine the motor threshold/motor evoked potential. Stimulation intensity for each patient was at 120% of the motor evoked potential.
Clinical data collected included: current use of psychiatric (antidepressant and antipsychotic) or migraine medication, and current psychotherapy and number of previous rTMS trials. The scales applied included: Hamilton Anxiety Scale (HAMA) [26], Hamilton Depression scale (HAMD) [27], WHOQOL-Bref (QoL) [28], Migraine Quality of Life (Migraine-QoL) [29], Headache Impact Test (HIT-6) [30], and Migraine Disability Assessment Test (MIDAS) [31]. All scales were administered at baseline and post-intervention by a licensed psychiatrist who was blinded to the rTMS protocol parameters and number of sessions received by each participant.
HAMA is a clinician-administered scale with 14 items measuring anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) with a total score range of 0–56. Higher scores represent worse anxiety levels.
HAMD is a clinician-administered scale with 17 items measuring depressive symptoms with higher scores representing more severe depression.
WHOQOL-BREF is a validated scale with 26 items used to measure quality of life across four domains: physical health, psychological health, social relationships and environment. Higher scores indicate better quality of life.
Migraine QoL is a 13-item scale used to evaluate quality of life specifically in participants diagnosed with migraine. It consists of 3 subscales: Role Restrictive, Role Preventive and Emotional Functioning. Higher scores indicate a better quality of life.
HIT-6 is a patient-reported questionnaire which measures the intensity of headache and its impact on daily functioning. It consists of 6 questions covering pain severity, social functioning, role functioning (work/home), cognitive functioning (concentration), vitality (energy levels) and psychological stress. Higher scores represent higher headache severity.
MIDAS is a short, self-administered questionnaire used to evaluate the disability due to headache during the previous 3 months. Questions cover days missed from school/work and reduced activity during free time. Higher scores show more disability.
Statistical Analysis
Descriptive statistics were used to characterize the sample. Categorical variables were presented as N (%), and continuous variables as mean (SD).
We computed the ΔQoL and ΔMigraine-QoL as the differences in total scores between the end-of-intervention timepoint and the baseline. Higher delta scores indicated greater improvement in QoL between the two timepoints. Raw change scores were used as dependent variables given the unidirectional intervention design and the absence of a control group, consistent with methodological guidance supporting their use when within-person change is the primary estimand of interest [32,33]. For the QoL variables we also applied a paired sample t-test to evaluate if the changes between timepoints were statistically significant. These scores were used in Spearman correlations (non-normal distribution) to identify which baseline scales correlated with changes in QoL. Non-normal distribution of QoL change scores was confirmed by Shapiro–Wilk testing (p < 0.05). The mean delta score for each QoL scale was individually compared between all the categorical variables to identify potential predictors. All significant variables were included in a linear regression analysis to identify independent predictors and potential confounders. All analyses were conducted with SPSS Statistics v26 and the significance threshold was p < 0.05.
Prior to regression analysis, all modeling assumptions were systematically verified. Normality of residuals was assessed using the Shapiro–Wilk test (W = 0.959, p = 0.265), confirming that residuals did not deviate significantly from a normal distribution. Homoscedasticity was evaluated using the Breusch-Pagan test (p = 0.40), with no evidence of heteroscedasticity detected. Multicollinearity among predictors was assessed using variance inflation factors (VIF): Age VIF = 1.130, rTMS sessions VIF = 1.195, HIT-6 VIF = 1.141, and HAMA VIF = 1.167, all well below the conventional threshold of 5, indicating no problematic collinearity. To account for multiple comparisons in the exploratory Spearman correlation analyses (12 tests across six baseline variables and two outcomes), Benjamini–Hochberg false discovery rate (FDR) correction was applied. Results are reported with both uncorrected p-values and BH-adjusted significance thresholds.
3. Results
The total sample comprised 32 participants; 71.9% were female, the mean age was 41.88 ± 15.94 years, and 87.5% resided in urban areas. The mean baseline HAMA was 17.69 (SD 3.16), consistent with mild-to-moderate anxiety, and HAMD was 15.41 (SD 4.25), indicating mild depression. The full description of the sample is presented in Table 1.
Table 1.
Social and demographic characteristics.
After computing the ΔQoL scores for both QoL scales and comparing sociodemographic and clinical characteristics, we found that the presence of antipsychotics was significantly associated with improvement in overall QoL (ΔQoL 18.57 ± 5.86 vs 11.80 ± 7.37, p = 0.026), while baseline HIT-6 and HAMA were significantly correlated with improved Migraine-QoL (p = 0.001 for HIT-6 and p = 0.013 for HAMA). The full comparisons are presented in Table 2 and Table 3. At the uncorrected level, higher baseline HIT-6 scores were significantly associated with greater ΔMigraine-QoL (ρ = 0.568, p = 0.001), as were higher baseline HAMA scores (ρ = 0.434, p = 0.013). No baseline variable was significantly associated with ΔQoL. Following Benjamini–Hochberg FDR correction across all 12 correlations, only the association between HIT-6 and ΔMigraine-QoL retained statistical significance. The HAMA × ΔMigraine-QoL association did not survive correction (p = 0.013) and should therefore be interpreted as exploratory and hypothesis-generating rather than confirmatory.
Table 2.
Comparison between ΔQol/ΔMigraine-QoL and categorical socio-demographic and clinical variables.
Table 3.
Correlations between baseline evaluations and ΔQoL/ΔMigraine-QoL.
The multivariate linear regression model for ΔMigraine-QoL was statistically significant (R2 = 0.514, Adjusted R2 = 0.442, F(4,27) = 7.129, p < 0.001). Higher baseline HIT-6 scores (B = 0.510, SE = 0.137, p = 0.001, 95% CI [0.228, 0.791]) were independently associated with greater improvement in Migraine-QoL. Baseline HAMA score, age and number of rTMS sessions did not independently predict ΔMigraine-QoL after accounting for the other confounders. The complete model is presented in Table 4.
Table 4.
Regression analysis of independent predictors for ΔMigraine-QoL.
4. Discussion
In this study, we examined predictors of quality of life (QoL) in patients with migraine undergoing repetitive transcranial magnetic stimulation (rTMS). The use of rTMS in migraine has gained increasing attention as a non-pharmacological neuromodulatory intervention, particularly for patients who are refractory to or intolerant of the available medication. Cortical hyperexcitability and maladaptive plasticity are thought to contribute not only to headache generation but also to sensory hypersensitivity, cognitive complaints, and affective symptoms. Consequently, rTMS may exert benefits that extend beyond pain reduction, potentially influencing QoL through improvements in emotional regulation, cognitive functioning, and perceived disability.
Previous clinical trials and meta-analyses have demonstrated that high-frequency rTMS can reduce headache days and migraine intensity [34]. However, comparatively fewer studies have examined predictors of quality-of-life outcomes, particularly from an exploratory perspective.
Our findings are consistent with prior studies demonstrating that migraine-related disability and QoL impairment are only partially explained by headache frequency alone [14], supporting the exploratory aim of the present study: to identify additional factors that may predict quality-of-life improvement following rTMS in patients with migraine. The magnitude of QoL improvement observed in this study exceeds the published Minimal Clinically Important Difference (MCID) thresholds for both instruments [35,36], suggesting that rTMS produced clinically meaningful rather than merely statistically detectable change. However, we note that MCID estimates vary by population and method of derivation, and that the absence of a control group means we cannot exclude the contribution of non-specific effects to the observed gains.
Antipsychotic use was associated with greater improvement in overall WHOQOL-BREF scores. Given the very small subgroup size (n = 7), this finding must be interpreted with extreme caution and is hypothesis-generating only. Future controlled studies should systematically record concurrent psychotropic medication use, as these agents may act as effect modifiers of rTMS-induced QoL improvement.
The regression analysis evaluating independent predictors of ΔMigraine-QoL demonstrated that higher baseline HIT-6 scores were independently associated with greater QoL gains. Specifically, lower baseline age and higher headache severity predicted larger improvements in Migraine-QoL after rTMS sessions. Across controlled studies, rTMS has been associated with reductions in headache-related impact as captured by HIT-6, a validated measure that correlates with QoL and functional impairment in migraine. However, effect sizes vary by protocol, target, and population [37,38]. Baseline affective symptom severity did not significantly impact Migraine-QoL after rTMS sessions.
The finding that higher baseline headache severity (HIT-6) predicted greater Migraine-QoL improvement warrants careful interpretation from a clinical psychiatry perspective. Patients with more severe headache impact at baseline are likely to carry a correspondingly greater burden of psychiatric comorbidity, including anxiety sensitivity, avoidance behaviors, and anticipatory distress between attacks—the so-called “interictal burden” [39]. When rTMS effectively reduces headache severity and its associated functional impairment, the downstream reduction in anxiety and depressive symptoms may generate a cascade of QoL improvements that extends well beyond pain relief. This is consistent with the broader neuromodulation literature, in which the antidepressant and anxiolytic effects of rTMS appear to be partially mediated by reductions in perceived disability rather than direct action on mood circuitry alone. The present data suggest that clinicians should pay particular attention to headache impact burden—not merely headache frequency—when selecting candidates for rTMS, as this may be a more sensitive indicator of likely QoL benefit. The predictive role of baseline HIT-6 can be interpreted in at least two complementary ways. First, a statistical floor/ceiling effect: patients with higher baseline headache impact have a greater absolute range available for improvement, making large positive change scores more mathematically attainable regardless of treatment mechanism [30]. Second, and more mechanistically, high HIT-6 scores may index a clinical phenotype in which central sensitization predominates—a state in which rTMS-induced modulation of corticospinal and descending inhibitory pathways may be particularly effective [9,40]. These interpretations are not mutually exclusive and should be distinguished in future studies through neurophysiological or neuroimaging biomarkers.
The differential performance of the two regression models—robust for Migraine-QoL (R2 = 0.514, p < 0.001) but non-significant for WHOQOL-BREF (R2 = 0.115, p = 0.490)—underscores an important distinction in construct sensitivity between generic and disease-specific quality-of-life instruments. Neither baseline anxiety or depression scores (HAMA and HAMD) nor the number of rTMS sessions emerged as significant independent predictors of overall QoL improvement, despite bivariate associations observed for Migraine-QoL and session count, respectively. This pattern suggests that therapeutic dose, like psychiatric symptom burden, does not independently determine broader quality-of-life outcomes when clinical and demographic factors are accounted for—consistent with evidence that rTMS response is shaped more by individual clinical characteristics than by session number alone [41,42]. The WHOQOL-BREF captures a broad range of life domains—including physical health, environmental quality, and social functioning—that may be less sensitive both to the anxiety-driven functional impairments and to the specific neurophysiological effects of rTMS dose captured by disease-specific instruments. Conversely, the Migraine-QoL’s emphasis on role restriction, role prevention, and emotional functioning more directly reflects the psychiatric burden of migraine, explaining why headache impact severity, anxiety, and therapeutic exposure correlate with changes in this instrument at the bivariate level, while their independent contributions become more precisely delineated in the multivariate model.
From a clinical psychiatry standpoint, this highlights the importance of using condition-specific QoL instruments alongside generic health-related QoL tools when evaluating treatment outcomes in populations with significant psychiatric comorbidity, as each instrument may capture different facets of patient recovery that are clinically meaningful but statistically independent.
Taken together, these findings position rTMS as a genuine neuropsychiatric intervention for migraine, rather than a purely neurological one. The present study contributes to a growing body of evidence calling for a reframing of migraine management that fully integrates psychiatric assessment, monitoring of affective symptom trajectories, and evaluation of patient-centered QoL outcomes. In clinical practice, this means that psychiatrists and neurologists should collaborate more systematically in the management of patients with comorbid migraine and mental health conditions, sharing outcome data, coordinating pharmacological and non-pharmacological treatment strategies, and agreeing on validated measurement tools that capture the full spectrum of patient burden. rTMS, with its transdiagnostic efficacy across pain and mood disorders, is well positioned as a bridge intervention between neurology and psychiatry [43]. Its implementation in multidisciplinary settings has the potential to address the significant unmet need in patients whose migraine and psychiatric symptoms have proven refractory to conventional unimodal treatments.
Future studies should aim to validate these findings in larger, controlled cohorts and to integrate standardized QoL instruments alongside neurophysiological and neuroimaging markers. Stratification based on baseline psychosocial burden, migraine chronification, and psychiatric comorbidity may help to identify the patient subgroups most likely to experience meaningful quality-of-life improvements following rTMS.
Limitations
While this exploratory study offers several insights, a number of limitations should be acknowledged. The study sample represents a multiply-selected, treatment-experienced population attending a specialist clinic, which limits generalizability to the broader migraine population. Referral bias, self-selection for an intensive non-pharmacological intervention, and high rates of concurrent psychotropic medication use may have inflated observed effect sizes and should be considered when interpreting the magnitude of QoL improvements reported. The relatively small sample size may have limited statistical power and warrants replication in larger samples. Also, while widely validated, both HAMA and HAMD are clinician-rated scales and the study would benefit from the inclusion of patient-reported outcomes for affective symptoms. Although antipsychotics showed a positive impact on overall QoL, further investigation of this mechanism would be valuable to better characterize the nature of this effect. The lack of a control group limits the strength of our evidence. Finally, the variable number of sessions (10–40) reflects clinical practice conditions and could represent a source of intervention heterogeneity that limits direct comparison of outcomes across participants.
5. Conclusions
This exploratory observational study demonstrates that rTMS is associated with significant and clinically meaningful improvements in both generic and migraine-specific quality of life in adults with migraine and concurrent psychiatric comorbidity. Baseline headache impact severity independently predicted greater gains in Migraine-QoL. These findings collectively underscore the neuropsychiatric complexity of migraine and the value of an integrated clinical approach that combines validated psychiatric assessment with neuromodulatory intervention. rTMS should be considered not merely as a neurological treatment for headache, but as a transdiagnostic intervention capable of addressing the affective, cognitive, and functional dimensions of migraine-related burden. Future research should investigate the mechanistic pathways through which psychiatric comorbidity, psychotropic medication, and rTMS interact to shape QoL trajectories, ideally within larger randomized controlled trials that include standardized psychiatric endpoints alongside migraine-specific outcomes.
Author Contributions
Conceptualization, R.Z., C.T. and A.P.; methodology, R.Z. and A.P.; validation, R.Z., L.C.R. and C.T.; formal analysis, A.P.; investigation, R.Z.; data curation, A.P. and R.Z.; writing—original draft preparation, R.Z., L.C.R. and A.P.; writing—review and editing, R.Z., L.C.R., A.P. and C.T.; visualization, R.Z.; supervision, C.T. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Inter Health Systems SRL (protocol code 1/01.09.2023 and date of approval 20 October 2023).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The data presented in this study are available on request from the corresponding author. The data are not publicly available due to ethical/privacy issues.
Acknowledgments
The authors would like to thank the personnel from Emerald Medical Center for their support.
Conflicts of Interest
Author Alexandru Pavel is employed by the company FutureMeds. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Abbreviations
The following abbreviations are used in this manuscript:
| rTMS | Repetitive transcranial magnetic stimulation |
| QoL | Quality of life |
| HAMA | Hamilton Anxiety Scale |
| HAMD | Hamilton Depression Scale |
| HIT-6 | Headache Impact Test |
| MIDAS | Migraine Disability Assessment Test |
References
- Migraine|National Institute of Neurological Disorders and Stroke n.d. Available online: https://www.ninds.nih.gov/health-information/disorders/migraine (accessed on 9 February 2026).
- Eldaief, M.C.; Press, D.Z.; Pascual-Leone, A. Transcranial magnetic stimulation in neurology: A review of established and prospective applications. Neurol. Clin. Pract. 2013, 3, 519–526. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Straube, A.; Andreou, A. Primary headaches during lifespan. J. Headache Pain 2019, 20, 35. [Google Scholar] [CrossRef] [Scilit]
- Al Ghadeer, H.A.; AlSalman, S.A.; Albaqshi, F.M.; Alsuliman, S.R.; Alsowailem, F.A.; Albusror, H.A.; AlAbdi, Z.I.; Alwabari, E.M.; Alturaifi, Z.A.; AlHajji, A.M.; et al. Quality of Life and Disability Among Migraine Patients: A Single-Center Study in AlAhsa, Saudi Arabia. Cureus 2021, 13, e19210. [Google Scholar] [CrossRef] [Scilit]
- Diamond, M. The Impact of Migraine on the Health and Well-Being of Women. J. Women’s Health 2007, 16, 1269–1280. [Google Scholar] [CrossRef] [Scilit]
- Haw, N.J.; Cabaluna, I.T.; Kaw, G.E.; Cortez, J.F.; Chua, M.P.; Guce, K. A cross-sectional study on the burden and impact of migraine on work productivity and quality of life in selected workplaces in the Philippines. J. Headache Pain 2020, 21, 125. [Google Scholar] [CrossRef] [Scilit]
- Munir, F.; Leka, S.; Griffiths, A. Dealing with self-management of chronic illness at work: Predictors for self-disclosure. Soc. Sci. Med. 2005, 60, 1397–1407. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Brandes, J.L. Migraine and Functional Impairment. CNS Drugs 2009, 23, 1039–1045. [Google Scholar] [CrossRef] [Scilit]
- Bernstein, C.; Burstein, R. Sensitization of the Trigeminovascular Pathway: Perspective and Implications to Migraine Pathophysiology. J. Clin. Neurol. 2012, 8, 89–99. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Hamelsky, S.W.; Lipton, R.B. Psychiatric Comorbidity of Migraine. Headache J. Head Face Pain 2006, 46, 1327–1333. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Shapiro, R.E.; Nicholson, R.A.; Seng, E.K.; Buse, D.C.; Reed, M.L.; Zagar, A.J.; Ashina, S.; Muenzel, E.J.; Hutchinson, S.; Pearlman, E.M.; et al. Migraine-Related Stigma and Its Relationship to Disability, Interictal Burden, and Quality of Life: Results of the OVERCOME (US) Study. Neurology 2024, 102, e208074. [Google Scholar] [CrossRef] [Scilit]
- Hilliard, T. Migraine in 2025: An update on management. Med. Today 2025, 26, 40–48. [Google Scholar]
- DeJulio, P.A.; Perese, J.K.; Schuster, N.M.; Oswald, J.C. Lasmiditan for the acute treatment of migraine. Pain Manag. 2021, 11, 437–449. [Google Scholar] [CrossRef] [Scilit]
- Jiang, Y.; Yuan, C.; Sun, P.; Li, C.; Wang, L. Efficacy and safety of high-frequency repetitive transcranial magnetic stimulation (rTMS) for migraine: A meta-analysis of randomized controlled trials. Acta Neurol. Belg. 2024, 124, 1167–1176. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Duan, S.; Ren, Z.; Xia, H.; Wang, Z.; Zheng, T.; Li, G.; Liu, L.; Liu, Z. Associations between anxiety, depression with migraine, and migraine-related burdens. Front. Neurol. 2023, 14, 1090878. [Google Scholar] [CrossRef] [Scilit]
- Karimi, L.; Wijeratne, T.; Crewther, S.G.; Evans, A.E.; Ebaid, D.; Khalil, H. The Migraine-Anxiety Comorbidity Among Migraineurs: A Systematic Review. Front. Neurol. 2021, 11, 613372. [Google Scholar] [CrossRef] [Scilit]
- Dresler, T.; Caratozzolo, S.; Guldolf, K.; Huhn, J.-I.; Loiacono, C.; Niiberg-Pikksööt, T.; Puma, M.; Sforza, G.; Tobia, A.; Ornello, R.; et al. Understanding the nature of psychiatric comorbidity in migraine: A systematic review focused on interactions and treatment implications. J. Headache Pain 2019, 20, 51. [Google Scholar] [CrossRef] [Scilit]
- Lefaucheur, J.-P.; Aleman, A.; Baeken, C.; Benninger, D.H.; Brunelin, J.; Di Lazzaro, V.; Filipović, S.R.; Grefkes, C.; Hasan, A.; Hummel, F.C.; et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014–2018). Clin. Neurophysiol. 2020, 131, 474–528. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Carpenter, L.L.; Aaronson, S.T.; Hutton, T.; Pages, K.; Rush, A.J.; Sackeim, H.A. The trajectory of symptom change over the course of transcranial magnetic stimulation for major depressive disorder. Brain Stimul. 2025, 18, 1887–1895. [Google Scholar] [CrossRef] [Scilit]
- Dahlberg, L.S.; Linnman, C.N.; Lee, D.; Burstein, R.; Becerra, L.; Borsook, D. Responsivity of periaqueductal gray connectivity is related to headache frequency in episodic migraine. Front. Neurol. 2018, 9, 61. [Google Scholar] [CrossRef] [Scilit]
- Knight, Y.E.; Goadsby, P.J. The periaqueductal grey matter modulates trigeminovascular input: A role in migraine? Neuroscience 2001, 106, 793–800. [Google Scholar] [CrossRef] [Scilit]
- Chung, S.W.; Hill, A.T.; Rogasch, N.C.; Hoy, K.E.; Fitzgerald, P.B. Use of theta-burst stimulation in changing excitability of motor cortex: A systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2016, 63, 43–64. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Huang, Y.-Z.; Edwards, M.J.; Rounis, E.; Bhatia, K.P.; Rothwell, J.C. Theta burst stimulation of the human motor cortex. Neuron 2005, 45, 201–206. [Google Scholar] [CrossRef] [Scilit]
- Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018, 38, 1–211. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- World Medical Association. Declaration of Helsinki, Ethical Principles for Scientific Requirements and Research Protocols; World Medical Association: Ferney-Voltaire, France, 2013; pp. 29–32. [Google Scholar]
- Hamilton, M. THE ASSESSMENT OF ANXIETY STATES BY RATING. Psychol. Psychother. Theory Res. Pract. 1959, 32, 50–55. [Google Scholar] [CrossRef] [Scilit]
- Hamilton, M. A RATING SCALE FOR DEPRESSION. J. Neurol. Neurosurg. Psychiatry 1960, 23, 56–62. [Google Scholar] [CrossRef] [Scilit]
- The Whoqol Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol. Med. 1998, 28, 551–558. [Google Scholar] [CrossRef] [Scilit]
- Caproni, S.; Bianchi, E.; Cupini, L.M.; Corbelli, I.; Beghi, E.; Calabresi, P.; Sarchielli, P.; SAMOHA Study Group. Migraine-specific quality of life questionnaire and relapse of medication overuse headache. BMC Neurol. 2015, 15, 85. [Google Scholar] [CrossRef] [Scilit]
- Yang, M.; Rendas-Baum, R.; Varon, S.F.; Kosinski, M. Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 2011, 31, 357–367. [Google Scholar] [CrossRef] [Scilit]
- Stewart, W.F.; Lipton, R.B.; Kolodner, K.B.; Sawyer, J.; Lee, C.; Liberman, J.N. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000, 88, 41–52. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Allison, P.D. Change Scores as Dependent Variables in Regression Analysis. Sociol. Methodol. 1990, 20, 93. [Google Scholar] [CrossRef] [Scilit]
- Vickers, A.J.; Altman, D.G. Analysing controlled trials with baseline and follow up measurements. BMJ 2001, 323, 1123–1124. [Google Scholar] [CrossRef] [Scilit]
- Matharu, M.S.; Silberstein, S.; Yuan, H.; Edgar, D.; Colman, R.; Schwedt, T.J.; Lanteri-Minet, M.; Obermann, M. Migraine-related disability according to headache frequency subclassifications: A systematic review and meta-analysis. Cephalalgia 2025, 45, 03331024251385965. [Google Scholar] [CrossRef] [Scilit]
- Cole, J.; Lin, P.; Rupnow, M. Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version 2.1. Cephalalgia 2009, 29, 1180–1187. [Google Scholar] [CrossRef] [Scilit]
- Pietrzykowski, M.O.; Vranceanu, A.-M.; Macklin, E.A.; Mace, R.A. Minimal clinically important difference in the World Health Organization Quality of Life Brief (WHOQOL-BREF) for adults with neurofibromatosis. Qual. Life Res. 2024, 33, 1233–1240. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Leahu, P.; Bange, M.; Ciolac, D.; Scheiter, S.; Matei, A.; Gonzalez-Escamilla, G.; Chirumamilla, V.C.; Groppa, S.A.; Muthuraman, M.; Groppa, S. Increased migraine-free intervals with multifocal repetitive transcranial magnetic stimulation. Brain Stimul. 2021, 14, 1544–1552. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Rendas-Baum, R.; Yang, M.; Varon, S.F.; Bloudek, L.M.; DeGryse, R.E.; Kosinski, M. Validation of the Headache Impact Test (HIT-6) in patients with chronic migraine. Health Qual. Life Outcomes 2014, 12, 117. [Google Scholar] [CrossRef] [Scilit]
- Sarkar, A.K.; Ghanbarian, E.; Fanning, K.M.; Urani, A.; Cadiou, F.; Lipton, R.B.; Ezzati, A. Impact of anxiety and depression on migraine-related disability: Results from the Headache Assessment via Digital Platform in the United States (HeAD-US) study. Clin. Neurol. Neurosurg. 2025, 258, 109172. [Google Scholar] [CrossRef] [Scilit]
- Russo, A.; Esposito, F.; Conte, F.; Fratello, M.; Caiazzo, G.; Marcuccio, L.; Giordano, A.; Tedeschi, G.; Tessitore, A. Functional interictal changes of pain processing in migraine with ictal cutaneous allodynia. Cephalalgia 2017, 37, 305–314. [Google Scholar] [CrossRef] [Scilit] [PubMed]
- Blumberger, D.M.; Vila-Rodriguez, F.; Thorpe, K.E.; Feffer, K.; Noda, Y.; Giacobbe, P.; Knyahnytska, Y.; Kennedy, S.H.; Lam, R.W.; Daskalakis, Z.J.; et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): A randomised non-inferiority trial. Lancet 2018, 391, 1683–1692. [Google Scholar] [CrossRef] [Scilit]
- Fitzgerald, P.B.; Hoy, K.E.; Reynolds, J.; Singh, A.; Gunewardene, R.; Slack, C.; Ibrahim, S.; Daskalakis, Z.J. A pragmatic randomized controlled trial exploring the relationship between pulse number and response to repetitive transcranial magnetic stimulation treatment in depression. Brain Stimul. 2020, 13, 145–152. [Google Scholar] [CrossRef] [Scilit]
- Fitzsimmons, S.M.; Oostra, E.; Postma, T.S.; van der Werf, Y.D.; van den Heuvel, O.A. Repetitive Transcranial Magnetic Stimulation–Induced Neuroplasticity and the Treatment of Psychiatric Disorders: State of the Evidence and Future Opportunities. Biol. Psychiatry 2024, 95, 592–600. [Google Scholar] [CrossRef] [Scilit] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.